TLR7/8 agonist NKTR-262 increased CD11c dendritic cell recruitment to tumors in melanoma, but a trial of NKTR-262 in combination with bempegaldesleukin with or without nivolumab was terminated. This evidence concerns the gene ITGAX and melanoma.